Development of Dolichos lablab loaded nanostructured lipid carriers for the mitigation of diabetes mellitus.

In recent years, nano technology emerged as a significant approach in drug delivery. Solid Lipid Nanoparticles are on forefront in field of nanotechnology, Lipid nanoparticles have an opportunity to create novel therapies because of their special size-dependent characteristics. This research work was aimed to formulate and optimize Dolichos lablab phytoextract fraction (DLPEF) loaded Nano Lipid Carrier (NLC) and to evaluate its anti-diabetic potential. DLPEF loaded nano lipid particles preparations were made using hot homogenization method and were characterized for particle size, shape, drug loading, in vitro drug release and were screened in-vivo for anti-diabetic activity. From our resulting data, an optimized formulation of DLPEF loaded NLC showed promising results. They were found to be spherical size of 104.7 nm, Polydispersity Index and Drug Loading for the optimized nanolipid carrier preparation were found at 0.667 ± 2.3 and 35.30 ± 3.2% respectively. The in vitro drug release for optimized NLC formulation was found to be 85% ± 2.2 for 18 h. No changes were observed in shape and morphology, confirmed through TEM and SEM after 3 months of stability studies. Diabetes was induced by Streptozotocin, DLPEF NLC treated group showed reduced glucose concentration. The histopathological alterations were also studied in all experimental groups, results of DLPEF NLC treated group showed regeneration of islet cells of pancreas. Thus we could concur that DLPEF NF has almost the same therapeutic potential as standard drug. In conclusion, Dolichos lablab phytoextract NLC substantially improved the solubility, stability and efficacy of the fraction making it a treatment option for diabetes mellitus.